| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap |
BoNT-A, NCT03181802: Are Paraspinous Intramuscular Injections of Botulinum Toxin A () Efficient in the Treatment of Chronic Low-back Pain (LBP)? |
|
|
| Completed | 3 | 19 | Europe | Botox, Placebos | University Hospital, Bordeaux | Chronic Low-back Pain | 05/05 | 05/05 | | |
NCT00682760: Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm |
|
|
| Completed | 3 | 60 | RoW | Korean Botulinum toxin type A (KbtxA) and Botox injection, arm1 ; Meditoxin or Neuronox | Pacific Pharmaceuticals | Blepharospasm | 02/06 | 08/06 | | |
2007-000919-29: Study on reversible effect on muscle of the botulinica toxin on the prevention of the post-traumatic rigidity of elbow |
|
|
| Ongoing | 3 | 60 | Europe | Powder for solution for injection, BOTOX | ISTITUTI ORTOPEDICI RIZZOLI | omero mono-Inter-sovra-sovraintercondiloidee fractures of distant them, fractures of capitello radial and fractures of olecrano with or without luxation | | | | |
NCT00408785: A Study Of BOTOX For The Treatment Of Glabellar Lines |
|
|
| Completed | 3 | 256 | RoW | Botulinum Toxin Type A, sodium chloride | GlaxoSmithKline | Glabellar Lines | 05/07 | 05/07 | | |
PREEMPT, NCT00156910: A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches |
|
|
| Completed | 3 | 679 | US, Canada | Botulinum Toxin Type A, BOTOX®, Placebo (saline) | Allergan | Migraine Disorders | 11/07 | 07/08 | | |
|
|
|
|
|
|
|
|
PREEMPT, NCT00168428: A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches |
|
|
| Completed | 3 | 705 | US, Canada, Europe, RoW | Botulinum Toxin Type A, BOTOX®, placebo (saline) | Allergan | Migraine Disorders | 12/07 | 08/08 | | |
|
|
|
|
|
|
|
NCT00373789: Refractory Urge Incontinence and Botox Injections |
|
|
| Terminated | 3 | 87 | US | Botulinum Toxin A, bladder detrusor muscle injection, Botox, Vehicle saline as placebo | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Urinary Incontinence, Detrusor Overactivity, Urinary Urgency, Urge Urinary Incontinence | 12/07 | 12/07 | | |
NCT00496964: Botox for Non-surgical Lateral Release in Patellofemoral Pain |
|
|
| Terminated | 3 | 5 | US | Botulinum toxin A + exercise, Botox, Placebo | Virginia Commonwealth University, Allergan | Patellofemoral Pain Syndrome | 06/08 | 06/08 | | |
2005-004637-17: A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase |
|
|
| Completed | 3 | 650 | Europe, RoW | BOTOX®, 9060X, Powder for solution for injection, BOTOX® | ALLERGAN LTD | Headache prophylaxis in migraine patients with 15 or more headache days per month | | 08/08 | | |
NCT00460564: Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity |
|
|
| Completed | 3 | 109 | Japan | GSK1358820, Placebo | GlaxoSmithKline | Post-Stroke Spasticity, Cerebrovascular Accident | 12/08 | 12/08 | | |
NCT00460655: Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity |
|
|
| Completed | 3 | 120 | Japan | GSK1358820, Placebo | GlaxoSmithKline | Post-Stroke Spasticity, Cerebrovascular Accident | 12/08 | 12/08 | | |
NCT01091727: Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity |
|
|
| Completed | 3 | 57 | Canada | Botulinum toxin A, Botox | Sunnybrook Health Sciences Centre, ethica Clinical Research Inc. | Neurogenic Detrusor Overactivity | 04/09 | 04/09 | | |
NCT00777803 / 2008-002713-40: NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines |
|
|
| Completed | 3 | 381 | Europe | NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®)), "Botulinum toxin type A (150 kiloDalton), free from complexing proteins", OnabotulinumtoxinA (Vistabel®), "BOTOX® Cosmetic", "Botulinum toxin type A (900 kiloDalton)" | Merz Pharmaceuticals GmbH | Glabellar Frown Lines | 04/09 | 05/09 | | |
NCT01791881: Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm |
|
|
| Completed | 3 | 172 | RoW | Hugeltox, Botulinum Toxin Type A(Botox®) | Hugel | Essential Blepharospasm | 05/09 | 07/09 | | |
NCT01018485: The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor |
|
|
| Completed | 3 | 30 | RoW | Botulinum Toxin Type A, Botox | Melbourne Health, Eastern Health | Multiple Sclerosis, Tremor | 02/10 | 06/10 | | |
NCT00461292: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder |
|
|
| Completed | 3 | 275 | US, Canada, Europe, RoW | botulinum toxin Type A (200U), BOTOX®, botulinum toxin Type A (300U), Normal saline (Placebo); botulinum toxin Type A (200U), Normal saline (Placebo); botulinum toxin Type A (300U) | Allergan | Overactive Bladder | 03/10 | 04/10 | | |
2007-000192-42: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX® in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity |
|
|
| Completed | 3 | 275 | Europe, RoW | Botox®, 9060X, Powder for solution for injection, BOTOX® | Allergan Ltd, ALLERGAN | Urinary incontinence due to neurogenic detrusor overactivity | | | | |
| Completed | 3 | 416 | US, Canada, Europe, RoW | botulinum toxin Type A (200U), BOTOX®, botulinum toxin Type A (300U), Normal Saline (Placebo); botulinum toxin Type A (200U), Normal Saline (Placebo); botulinum toxin Type A (300U) | Allergan | Overactive Bladder | 05/10 | 05/10 | | |
NCT01429402: Botulinum Toxin to Improve Results in Cleft Lip Repair |
|
|
| Unknown status | 3 | 120 | RoW | Botulinum Toxin Type A, Botox ( Allergan, Inc., Irvine, Calif), Botulinum Type A, Normal Saline, NaCl 0.9% | Chang Gung Memorial Hospital | Scar | 08/10 | 08/13 | | |
NCT01237977: Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines |
|
|
| Completed | 3 | 314 | RoW | Botulinum Toxin Type A(Meditoxin®), Neuronox®, Siax®, Botulinum Toxin Type A(Botox®) | Medy-Tox | Skin Aging | 08/10 | 09/10 | | |
| Completed | 3 | 917 | Canada, US, Europe | onabotulinumtoxinA 24 U, BOTOX®, BOTOX® Cosmetic, onabotulinumtoxinA, onabotulinumtoxinA 44 U, normal saline | Allergan | Facial Rhytides, Crow's Feet Lines, Glabellar Lines | 03/11 | 09/11 | | |
| Completed | 3 | 446 | Canada, US, Europe | onabotulinumtoxinA, BOTOX®, BOTOX® Cosmetic, normal saline | Allergan | Lateral Canthus Rhytides, Crow's Feet Lines | 04/11 | 07/11 | | |
NCT01220726: Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction |
|
|
| Completed | 3 | 30 | US | Botox, Placebo | Weill Medical College of Cornell University | Overactive Bladder | 06/11 | 11/12 | | |
NCT01153815: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity |
|
|
| Completed | 3 | 170 | RoW | GSK1358820(Botulinum toxin type A), OnabotulinumtoxinA, Botox, placebo | GlaxoSmithKline | Cerebrovascular Accident | 06/11 | 06/11 | | |
NCT00910845: Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence |
|
|
| Completed | 3 | 557 | US, Canada | onabotulinumtoxinA, BOTOX®, botulinum toxin Type A, normal saline | Allergan | Overactive Bladder | 07/11 | 07/11 | | |
| Completed | 3 | 548 | US, Europe, RoW | onabotulinumtoxinA, BOTOX®, botulinum toxin Type A, normal saline | Allergan | Overactive Bladder | 08/11 | 08/11 | | |
NCT01128738: GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis |
|
|
| Completed | 3 | 152 | Japan | GSK1358820, Placebo | GlaxoSmithKline | Hyperhidrosis | 08/11 | 08/11 | | |
| Completed | 3 | 684 | US, Canada, Europe | normal saline, onabotulinumtoxinA 44 U, BOTOX®, BOTOX® Cosmetic, onabotulinumtoxinA, onabotulinumtoxinA 24 U | Allergan | Facial Rhytides, Crow's Feet Lines, Glabellar Lines | 10/11 | 02/12 | | |
NCT01180348: Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines |
|
|
| Completed | 3 | 192 | RoW | Botulift, Botulinum Toxin Type A, Botox | Azidus Brasil, Laboratório Químico Farmacêutico Bergamo Ltda. | Wrinkles | 10/11 | 09/12 | | |
NCT01205451: A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity |
|
|
| Completed | 3 | 109 | RoW | Botulinum toxin type A | GlaxoSmithKline | Spasticity, Post-Stroke | 12/11 | 03/12 | | |
NCT01791920: To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines |
|
|
| Completed | 3 | 262 | RoW | Botulinum toxin type A(Botulax®), Botulinum toxin type A(Botox®) | Hugel | Skin Aging | 12/11 | 03/12 | | |
| Terminated | 3 | 25 | US | Botox Instillation, Botulinum-A Toxin, Botox, DMSO Instillation, Dimethyl Sulfoxide, DMSO | Mayo Clinic | Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Urge Incontinence | 01/12 | 01/12 | | |
NCT01313767: MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity |
|
|
| Completed | 3 | 196 | RoW | Botulinum toxin type A, Neuronox®, Siax®, Botulinum Toxin type A, Botox® | Medy-Tox | Spasticity | 01/12 | 02/12 | | |
NCT01716624: Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder |
|
|
| Completed | 3 | 20 | Canada | Oxybutynin, Botulinum Toxin A injection | Lawson Health Research Institute | Neurogenic Bladder | 03/12 | 04/12 | | |
| Completed | 3 | 249 | US | Botulinum toxin A (Botox A®), (Botox A®), Solifenacin 5mg, Vesicare, Solifenacin 10mg, Trospium chloride, Sanctura | NICHD Pelvic Floor Disorders Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Urge Urinary Incontinence, Overactive Bladder | 05/12 | 05/12 | | |
2007-001602-24: Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) |
|
|
| Completed | 3 | 68 | Europe | Botox (R), Tamsulosin STADA (TM), Injection*, Capsule, hard, Botox (TM), Tamsulosin STADA (TM) | Department of Urology and Pediatric Urology - Justus-Liebig-University Giessen | chronic prostatitis / chronic pelvic pain syndrom | | 07/12 | | |
NCT03894748: Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L) |
|
|
| Completed | 3 | 168 | RoW | Botulinum Toxin Type A | Medy-Tox | Glabella Line Severity | 08/12 | 10/12 | | |
NCT01629875: Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line |
|
|
| Completed | 3 | 268 | RoW | Generic equivalent of Clostridium Botulinum A Toxin, Botox (Clostridium Botulinum A Toxin) | Daewoong Pharmaceutical Co. LTD. | Moderate to Severe Glabellar Line | 08/12 | 11/12 | | |
BOLLD, NCT00412035: Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery |
|
|
| Completed | 3 | 125 | US, Canada | Botulinum toxin A injection, botox, saline injection, salt water | Shriners Hospitals for Children | Unequal Length of Limbs; Congenital, Lower Extremity Deformities, Congenital | 12/12 | 12/12 | | |
NCT00439140: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder |
|
|
| Terminated | 3 | 41 | US, Canada, RoW | botulinum toxin Type A, BOTOX®, onabotulinumtoxinA, Normal Saline (Placebo) | Allergan | Overactive Bladder | 12/12 | 12/12 | | |
| Terminated | 3 | 11 | Europe | Botulinum Toxin Type A, Botox, Placebo | Daniel Stephan Engeler, Allergan | Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Prostatitis | 05/13 | 06/13 | | |
NCT01586819: Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A |
|
|
| Completed | 3 | 26 | US | Botulinum Toxin, Botox, Chemical Peel Only, Jessner's peel solution, TCA peel | Loyola University | Wrinkles | 05/13 | 05/13 | | |
NCT00876447 / 2009-009216-53: A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis |
|
|
| Completed | 3 | 397 | Canada, US, Europe, RoW | Botulinum Toxin Type A 300U, BOTOX®, Botulinum Toxin Type A 200U | Allergan | Overactive Bladder | 06/13 | 09/13 | | |
NCT01584843: Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus |
|
|
| Completed | 3 | 41 | Japan | GSK1358820, Botulinum Toxin Type A | GlaxoSmithKline | Strabismus | 07/13 | 06/14 | | |
NCT01797094: BOTOX® in the Treatment of Upper Facial Lines in Japan |
|
|
| Completed | 3 | 101 | Japan | botulinum toxin Type A (44U), BOTOX®, botulinum toxin Type A (32U) | Allergan | Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Frown Lines | 07/13 | 07/14 | | |
NCT01797081: BOTOX® in the Treatment of Crow's Feet Lines in Japan |
|
|
| Completed | 3 | 300 | Japan | botulinum toxin Type A (24 U), BOTOX®, botulinum toxin Type A (12 U), Normal Saline | Allergan | Lateral Canthus Rhytides, Crow's Feet Lines | 07/13 | 07/14 | | |
APTODON, NCT01325090: Early Administration of Botox® in Neuropathic Pain Due to Thoracoscopy or Thoracotomy |
|
|
| Withdrawn | 3 | 0 | NA | BOTOX, PLACEBO | University Hospital, Limoges | Pain Due to Certain Specified Procedures, Neuropathic Pain | 11/13 | 11/14 | | |
NCT01600716 / 2012-000957-30: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) |
|
|
| Completed | 3 | 144 | Canada, US, Europe, RoW | OnabotulinumtoxinA, BOTOX®, botulinum toxin Type A, Placebo (Normal Saline) | Allergan | Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder | 04/14 | 03/15 | | |
NCT01915459: Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity |
|
|
| Completed | 3 | 186 | RoW | Botulinum toxin type A(Botulax®), Botulinum toxin type A(Botox®) | Hugel | Stroke, Spasticity | 05/14 | 07/14 | | |
NCT01945684: A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity |
|
|
| Completed | 3 | 197 | RoW | Botulinum toxin type A, Assigned Interventions, Experimental: DWP450, Botulinum toxin type A Drug: Botulinum toxin type A, Active Comparator: Botox®, Botulinum Toxin type A Drug: Botulinum Toxin type A (Botox®) | Daewoong Pharmaceutical Co. LTD. | Spasticity, Stroke | 05/14 | 07/14 | | |
NCT03908008: Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line |
|
|
| Completed | 3 | 136 | NA | Botox (Botulinum toxin type A), MT10107 (Botulinum toxin type A) | Medy-Tox | Glabellar Frown Lines | 05/14 | 09/14 | | |
NCT01787344: Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy |
|
|
| Completed | 3 | 144 | RoW | Botulinum Toxin Type A(Botox®), Botulinum toxin type A(Botulax®) | Hugel | Other Infantile Cerebral Palsy | 06/14 | 08/14 | | |
| Completed | 3 | 152 | NA | Medytoxin, botulinum type A toxin, Botox | Medy-Tox | Cervical Dystonia | 07/14 | 08/14 | | |
NCT00915525 / 2009-013089-26: Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence |
|
|
| Completed | 3 | 829 | Canada, US, Europe, RoW | botulinum toxin Type A, BOTOX® | Allergan | Overactive Bladder, Urinary Incontinence | 08/14 | 08/14 | | |
| Completed | 3 | 54 | Europe | botulinum toxin intramuscular injection, Botox, Allergan. | Guy's and St Thomas' NHS Foundation Trust | Cerebral Palsy, Post-operative Pain | 09/14 | 01/15 | | |
| Completed | 3 | 468 | US, Canada, Europe, RoW | botulinum toxin Type A, BOTOX®, onabotulinumtoxin A, Normal Saline | Allergan | Muscle Spasticity | 09/14 | 07/15 | | |
NCT01767519 / 2012-003255-11: A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence |
|
|
| Completed | 3 | 356 | Canada, US, Europe, RoW | BOTOX®, onabotulinumtoxinA, botulinum toxin Type A, solifenacin, Vesicare, Botox placebo (normal saline), solifenacin placebo | Allergan | Overactive Bladder, Urinary Incontinence | 09/14 | 03/15 | | |
NCT02195687: BOTOX® in the Treatment of Crow's Feet Lines in China |
|
|
| Completed | 3 | 417 | RoW | botulinum toxin Type A, BOTOX®, Normal Saline | Allergan | Lateral Canthal Lines, Crow's Feet Lines | 02/15 | 06/15 | | |
NCT01829763: Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower Limb |
|
|
| Unknown status | 3 | 20 | Europe | injection botox | Assistance Publique Hopitaux De Marseille | Hemiplegic Patients Post-AVC | 04/15 | 11/15 | | |
2010-020944-37: Pilot study to establish laboratory methods for urine Nerve Growth Factor (NGF) and immunohistochemical staining of the vanilloid receptor (TRPV1) in bladder biopsies, following open label treatment with botulinum neurotoxin type A in patients with neurogenic detrusor overactivity (NDO) and idiopathic detrusor overactivity (IDO). |
|
|
| Completed | 3 | 20 | Europe | Botulinum neurotoxin type A, Concentrate for solution for injection, Botox | University College London | Neurogenic & Idiopathic detrusor overactivity in the bladder | | 05/15 | | |
| Completed | 3 | 787 | US, Europe | OnabotulinumtoxinA, BOTOX® Cosmetic, botulinum toxin Type A, Normal Saline | Allergan | Facial Rhytides, Glabellar Rhytides | 06/15 | 04/16 | | |
| Completed | 3 | 421 | Canada, US, Europe | OnabotulinumtoxinA, BOTOX® Cosmetic, botulinum toxin Type A, Normal Saline | Allergan | Forehead Rhytides, Glabellar Rhytides | 06/15 | 04/16 | | |
2014-002068-34: Residual Limb Hyperhidrosis Treatment : Aluminium Chloride versus Onabotulinumtoxin A Traitement de l’hyperhidrose des membres résiduels : sels d’aluminium versus toxine botulique |
|
|
| Ongoing | 3 | 54 | Europe | Powder for solution for injection, BOTOX, 100 units | DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES, DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES | Residual Limb Hyperhidrosis is the investigated medical condition., Amputees often suffer from hyperhidrosis (important production of sweat), which is responsible for prosthesis function impairments, dermatological problems and quality of life impairments., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
NCT02165111: Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome |
|
|
| Completed | 3 | 40 | US | Onabotulinumtoxin A, Botox, Botulinum toxin, Dysport, sterile saline solution, Saline | Johns Hopkins University, Allergan | Scleroderma, Raynaud's Syndrome | 09/15 | 09/15 | | |
NCT01422161: Study of Botulinum Toxin and Recovery of Hand Function After Stroke |
|
|
| Completed | 3 | 16 | US | Botulinum Toxin commonly known as BOTOX®, BOTOX®, Saline, Placebo | NYU Langone Health, Allergan | Stroke With Hemiparesis | 10/15 | 10/15 | | |
| Terminated | 3 | 53 | US, Canada | onabotulinumtoxinA, BOTOX®, botulinum toxin type A, placebo (normal saline) | Allergan | Muscle Spasticity, Stroke | 12/15 | 12/15 | | |
2005-002335-27: Botulin Toxin injection for the treatment of Internal Anal Sphincter Achalasia |
|
|
| Ongoing | 3 | | Europe | NA, NA, BOTOX*INIETT. 1 FL 100 U, BOTOX*INIETT. 1 FL 100 U | ISTITUTO GIANNINA GASLINI | Treatment of internal anal sphincter achalasia | | | | |
2005-003068-47: Behandling med botulinumtoxin vid neurogen blåsfunktionsstörning |
|
|
| Ongoing | 3 | 40 | Europe | Botox, Botox, Botox | Region Skåne, Universitetssjukhuset i Lund, Urologiska kliniken | The trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as behavioral techniques, physiotherapy, intermittent catheterisation or pharmacotherapy. | | | | |
2007-000534-39: etude comparative randomisee intra-individuelle de l\'efficacite du traitement d\'hidradenite suppuree ou maladie de verneuil par injections sous cutanee de toxine botulinique versus placebo |
|
|
| Ongoing | 3 | 32 | Europe | botox, botox, | acep | L’hidradénite suppurée est une affection des glandes sudorales apocrines. Les glandes apocrines sont sous la dépendance des terminaisons nerveuses orthosympathiques . Le mécanisme d’action de la toxine botulinique est le blocage de la transmission cholinergique des glandes sudorales . Nous avons rapporter l’efficacité de la toxine botulinique pour le traitement de la maladie de Verneuil et nous souhaitons vérifier l’efficacité de ce traitement par une étude en double aveugle | | | | |
2006-006299-39: A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment |
|
|
| | 3 | 20 | Europe | BOTOX®, 9060X, BOTOX®, BOTOX® | Allergan | Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy and have neurological respiratory impairment. | | | | |
2009-012431-15: Možnosti terapeutického ovlivnění neurogenního hyperaktivního detruzoru u pacientů po spinálním poranění a s roztroušenou sklerózou aplikací botulinumtoxinu A. Prospektivní, otevřená studie porovnávající efekt aplikace 300 U Botoxu® při podání do detruzoru močového měchýře a subslizničního podání.Therapeutic Use of Botulinum-A toxin in Neurogenic Detrusor Overactivity in Patient after Spinal Cord Injury and Multiple Sclerosis. A Prospective, Open Study with Comparison of Suburothelial and Intradetrusor Application of 300 U of Botox®. |
|
|
| Ongoing | 3 | 40 | Europe | Botox, Botox | Krajská nemocnice Liberec, a.s. | Studie se zabývá léčbou hyperaktivního neurogeního detruzoru u pacientů, kteří trpí příznaky hyperaktivního močového měchýře jako důsledek spinálního poranění nebo roztroušené sklerózy. K léčbě se pužívá botulinumotoxin. Ve studii se porovnávaní dvě různé formy aplikace studjiního léku. | | | | |
2009-018226-29: The effect of botulinum toxin type A injections in the m. rectus femoris in stroke patients presenting with a stiff knee gait. |
|
|
| Ongoing | 3 | 26 | Europe | Botox, RVG17379, | | Stroke patients with stiff knee gait. Stiff knee gait is characterized as a diminished knee flexion during swing phase of gait. It is common in stroke patients. | | | | |
2009-017412-32: RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE |
|
|
| Completed | 3 | 76 | Europe | Powder for solution for injection, Solution for injection, BOTOX, NEUROBLOC | AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI | Parkinson disease | | | | |
2012-004795-19: Utilisation of botulinum toxin type A on masticatory muscel hyperactivity in CP. Utvärdering av injektioner med botulinum toxin vid tuggmuskulär hyperaktivitet hos individer med cerebral pares. |
|
|
| Ongoing | 3 | 16 | Europe | Botox, Concentrate and solvent for solution for injection, Botox Allergan | Folktandvården Västra Götaland, Folktandvården Västra Götaland | Masticatory muscle hyperactivity/bruxism in patients with Cerebral Palsy. Tuggmuskulär hyperaktivitet/bruxism hos personer med cerebral pares., Masticatory muscle hyperactivity/bruxism in patients with Cerebral Palsy. Tuggmuskulär hyperaktivitet/bruxism hos personer med cerebral pares., Diseases [C] - Nervous System Diseases [C10] | | | | |
2010-018298-39: Prospective Randomised Double-blind Sham Study on the Use of Botox for the Treatment of Diffuse esophageal spasm |
|
|
| Ongoing | 3 | 30 | Europe | Botox, Botox | UZLeuven | the effect of Botox on symptoms and manometry patterns in patients with diffuse esophageal spasm. | | | | |
2015-004391-29: Effectiveness of intragastric injection of botulinum toxin obese patients Eficacia de la inyección intragástrica de toxina botulínica en pacientes obesos |
|
|
| Completed | 3 | 60 | Europe | botulinum toxin, 93384-43-1, Powder for concentrate for solution for injection/infusion, BOTOX | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS), FIMABIS | Morbid obesity Obesidad mórbida, Obesity Obesidad, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2014-001063-12: A clinical trial demonstrating the safety and efficacy of treatment of lines between the eye brows with the test drug DWP-450 in adults by comparison with Botox and Placebo. |
|
|
| Completed | 3 | 497 | Europe, RoW | Botox, DWP-450, Powder for solution for injection, Nabota, Botox, 100 Allergan Units | Evolus Inc., Evolus Inc. | moderate-to-severe glabellar lines, lines between the eyebrows and above the nose, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
TBIDE, NCT02816151: Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses |
|
|
| Completed | 3 | 29 | Europe | full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox, half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox | CHU de Reims | Neurogenic Vesical Hyperactivity Syndrom | 05/16 | 05/16 | | |
NCT01502956: Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) |
|
|
| Completed | 3 | 386 | US | InterStim® device, Botox® injection, Botox | NICHD Pelvic Floor Disorders Network, Duke University, University of Alabama at Birmingham, University of California, San Diego, The Cleveland Clinic, Brown University, University of New Mexico, University of Pennsylvania, University of Pittsburgh, Oregon Health and Science University, RTI International, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Urinary Incontinence, Urge | 07/16 | 07/16 | | |
NCT02450526: Dysport in the Treatment of Glabellar Lines in Chinese Subjects |
|
|
| Completed | 3 | 520 | RoW | Botulinum toxin type A, AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), Placebo | Ipsen | Glabellar Lines | 07/16 | 09/17 | | |
NCT01662492: A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine |
|
|
| Completed | 3 | 125 | US | Botulinum toxin type A Dose 1, onabotulinumtoxinA, BOTOX®, Botulinum toxin type A Dose 2, Placebo (Normal Saline) | Allergan | Migraine Disorders | 08/16 | 08/16 | | |
NCT02160535: Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA |
|
|
| Terminated | 3 | 13 | US | OnabotulinumtoxinA, BOTOX | University of Washington | Chronic Post Traumatic Headache | 08/16 | 08/16 | | |
NCT03216408: Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 504 | NA | Neuronox, Clostridium Botulinum Toxin A 100 U, Botox, Clostridium Botulinum Toxin A 50 U | Medy-Tox | Glabellar Lines | 11/16 | 03/17 | | |
NCT02767635: Comparison Between Steroid and Different Sites of Botulinum Toxin Injection in the Treatment of Lateral Epicondylalgia |
|
|
| Unknown status | 3 | 90 | RoW | Botox-Epic, onabotulinumtoxinA, Botox-Tend, triamcinolone acetonide (Steroid), steroid | National Cheng-Kung University Hospital | Tennis Elbow | 12/16 | 12/16 | | |
NCT02078895: Randomization of Botox for Stent Pain and Irritative Voiding Symptoms |
|
|
| Terminated | 3 | 15 | US | Botox, Botulinum Toxin Type A | University of California, Irvine | Lower Urinary Tract Discomfort, Stent Pain | 02/17 | 02/17 | | |
NCT03216473: Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm |
|
|
| Completed | 3 | 140 | NA | Neuronox, Botulinum Toxin Type A for injection, Botox | Medy-Tox | Essential Blepharospasm | 03/17 | 07/17 | | |
2014-005114-33: Effectiveness of botox injections in the pectoral muscles for treatment of upper limb dysfunctions after breast cancer treatment |
|
|
| Completed | 3 | 50 | Europe | Botox, Powder for solution for injection, BOTOX | UZ Leuven, UZ Leuven | The aim of this study is to examine the effect of Botolinum Toxine infiltration in the pectoral muscle, in combination with an individual physical therapy programme, on pain and upper limb dysfunctions in women after breast cancer, To examine the effect of botox infiltration in the pectoral muscle, in combination with an individual physical therapy programme, on pain and upper limb dysfunctions in women after breast cancer, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Withdrawn | 3 | 0 | US | onabotulinumtoxinA, BOTOX®, botulinum toxin type A | Allergan | Muscle Spasticity, Stroke | 05/17 | 05/17 | | |
| Completed | 3 | 384 | US, Europe, RoW | botulinum toxin Type A, BOTOX®, Normal Saline (Placebo) | Allergan | Pediatrics, Muscle Spasticity, Cerebral Palsy | 06/17 | 06/17 | | |
| Completed | 3 | 235 | Canada, US, Europe, RoW | botulinum toxin Type A, BOTOX®, onabotulinumtoxinA, Normal Saline (Placebo) | Allergan | Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke | 06/17 | 07/17 | | |
NCT01591746: Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction |
|
|
| Completed | 3 | 131 | US | Botulinum Toxin Type A, BOTOX, Placebo, Sodium chloride solution | Mayo Clinic, Allergan | Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms | 07/17 | 07/17 | | |
FOLOTOX, NCT01821573: Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength During Locomotion in Chronic Hemiparetic Patients |
|
|
| Completed | 3 | 36 | Europe | botulinum toxin type A, Botox® allergan Inc, injection of NaCl 0.9% | Assistance Publique - Hôpitaux de Paris, Allergan | COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO | 09/17 | 05/19 | | |
| Completed | 3 | 250 | RoW | botulinum toxin type A, MEDITOXIN, BOTOX | Medy-Tox | Crow's Feet Lines | 12/17 | 05/18 | | |
NCT05380154: Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines. |
|
|
| Completed | 3 | 500 | RoW | Botulinum Toxin A type for injection (Botulax®), Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®) | Hugel, Sihuan Pharmaceutical Limited | Glabellar Lines | 01/18 | 07/18 | | |
NCT02849418: Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity |
|
|
| Completed | 3 | 21 | Japan | GSK1358820, Placebo | GlaxoSmithKline | Urinary Bladder, Overactive | 03/18 | 12/18 | | |
2014-001068-36: Botox versus extended release tolterodine in the management ofoveractive bladder in children |
|
|
| Completed | 3 | 60 | Europe | Onabotulinum toxin A, Tolterodine, Tolterodine XL, Powder for injection, Capsule, hard, Botox, Tolterodine XL | Central Manchester University Hospitals NHS Foundation Trust, National Institute for Health Research | Idiopathic Overactive Bladder, Overactive bladder, Diseases [C] - Symptoms and general pathology [C23] | | | | |
NCT02820844: Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder |
|
|
| Completed | 3 | 250 | Japan | GSK1358820, Placebo, Antibiotic therapy, Bladder diary, King's Health Questionnaire (KHQ), Overactive Bladder Symptom Score (OABSS), Treatment Benefit Scale (TBS) | GlaxoSmithKline | Urinary Bladder, Overactive | 03/18 | 11/18 | | |
NCT03261167: A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity |
|
|
| Completed | 3 | 124 | Japan | Botulinum toxin A (GSK1358820), Placebo | GlaxoSmithKline | Spasticity, Post-Stroke | 03/18 | 01/19 | | |
| Active, not recruiting | 3 | 100 | | | University of Melbourne, NHMRC | Multiple Sclerosis, Tremor | | | | |
NCT03289702: CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3) |
|
|
| Completed | 3 | 220 | RoW | CORETOX®, BOTOX® | Medy-Tox | Muscle Spasticity | 06/18 | 11/18 | | |
